Media Summary: Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the latest developments in KRAS ... Presented At: LabRoots - Drug Discovery Virtual Event 2019 Presented By: Khyati Shah, PhD - Post Doctoral Research Scholar at ...

Optimizing Combination Therapies To Overcome - Detailed Analysis & Overview

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the latest developments in KRAS ... Presented At: LabRoots - Drug Discovery Virtual Event 2019 Presented By: Khyati Shah, PhD - Post Doctoral Research Scholar at ... 2022 Vitiligo International Symposium Thierry Passeron, MD, PhD. Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses key challenges in At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel ...

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses how researchers are working to Future considerations for treating advanced cholangiocarcinoma with Sylvia Plevritis, Stanford University Computational Cancer Biology Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the various therapeutic strategies available for the ... Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the Heart failure remains a leading cause of hospitalization, prompting ongoing research into

Photo Gallery

Optimizing combination therapies to overcome PARP inhibitor resistance
Optimizing and overcoming resistance to current KRAS inhibitors
Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance
Invited Speaker: Optimizing Combination Therapies for the Best Results in Vitiligo
Optimizing immunotherapy: predictive biomarkers, resistance strategies & personalized medicine
Optimizing proteasome inhibitors for the treatment of multiple myeloma
Strategies for Optimizing Immune Checkpoint Inhibition in Urothelial Carcinoma
Optimizing Therapy for Advanced Cholangiocarcinoma
Optimizing Combination Cancer Therapy Based on Single Cell Analysis
Optimizing treatment approaches for ER+/HER2- breast cancer
Optimizing chemotherapy combinations for AML
Charting the Course for Metastatic Breast Cancer Care: Optimizing First-Line Treatment and Beyond
Sponsored
Sponsored
View Detailed Profile
Optimizing combination therapies to overcome PARP inhibitor resistance

Optimizing combination therapies to overcome PARP inhibitor resistance

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on

Optimizing and overcoming resistance to current KRAS inhibitors

Optimizing and overcoming resistance to current KRAS inhibitors

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the latest developments in KRAS ...

Sponsored
Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance

Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance

Presented At: LabRoots - Drug Discovery Virtual Event 2019 Presented By: Khyati Shah, PhD - Post Doctoral Research Scholar at ...

Invited Speaker: Optimizing Combination Therapies for the Best Results in Vitiligo

Invited Speaker: Optimizing Combination Therapies for the Best Results in Vitiligo

2022 Vitiligo International Symposium Thierry Passeron, MD, PhD.

Optimizing immunotherapy: predictive biomarkers, resistance strategies & personalized medicine

Optimizing immunotherapy: predictive biomarkers, resistance strategies & personalized medicine

Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses key challenges in

Sponsored
Optimizing proteasome inhibitors for the treatment of multiple myeloma

Optimizing proteasome inhibitors for the treatment of multiple myeloma

At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel ...

Strategies for Optimizing Immune Checkpoint Inhibition in Urothelial Carcinoma

Strategies for Optimizing Immune Checkpoint Inhibition in Urothelial Carcinoma

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses how researchers are working to

Optimizing Therapy for Advanced Cholangiocarcinoma

Optimizing Therapy for Advanced Cholangiocarcinoma

Future considerations for treating advanced cholangiocarcinoma with

Optimizing Combination Cancer Therapy Based on Single Cell Analysis

Optimizing Combination Cancer Therapy Based on Single Cell Analysis

Sylvia Plevritis, Stanford University Computational Cancer Biology https://simons.berkeley.edu/talks/sylvia-plevritis-02-04-2016.

Optimizing treatment approaches for ER+/HER2- breast cancer

Optimizing treatment approaches for ER+/HER2- breast cancer

Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the various therapeutic strategies available for the ...

Optimizing chemotherapy combinations for AML

Optimizing chemotherapy combinations for AML

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the

Charting the Course for Metastatic Breast Cancer Care: Optimizing First-Line Treatment and Beyond

Charting the Course for Metastatic Breast Cancer Care: Optimizing First-Line Treatment and Beyond

ADCs as first-line

Can Combination Therapy Optimize Heart Failure Care?

Can Combination Therapy Optimize Heart Failure Care?

Heart failure remains a leading cause of hospitalization, prompting ongoing research into